- NGM Biopharmaceuticals press release ( NASDAQ: NGM ): Q3 GAAP EPS of -$0.59 beats by $0.02 .
- Revenue of $7.91M (-57.4% Y/Y) beats by $0.85M .
- NGM Bio reported a net loss of $47.3 million for the quarter ended September 30, 2022, compared to a net loss of $28.9 million for the same period in 2021.
- Cash, cash equivalents and short-term marketable securities were $300.2 million as of September 30, 2022, compared to $366.3 million as of December 31, 2021.
For further details see:
NGM Biopharmaceuticals GAAP EPS of -$0.59 beats by $0.02, revenue of $7.91M beats by $0.85M